Cardinal Health reported solid financial results for Q1 2008, with sales up 5% and operating earnings up 9%. However, the Supply Chain Pharma segment performed below expectations, with market factors and poor execution dampening growth. Clinical and Medical Products continued its strong growth, with revenues up 25% and profits up 60%, driven by demand for medication management and infection prevention technologies. While disappointed in Supply Chain Pharma, Cardinal is making changes to improve execution and remains on track to meet full-year EPS guidance, expecting improved performance in the second half from increased generics and operational improvements.